Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Salmonella-IL2
- Development stage
- Phase 2
- Lead developer
- Salspera
- Modality
- Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Gene Therapies, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
Salmonella-IL2 (also known as Saltikva) is an orally administered, genetically engineered attenuated strain of *Salmonella typhimurium* that carries the human gene for interleukin-2 (IL-2)[1][4][5]. This live biotherapeutic product is designed to selectively colonize solid tumors and locally release IL-2 within the tumor microenvironment. The local expression of IL-2 stimulates natural killer (NK) cell proliferation and activity, enhancing anti-tumor immune responses while minimizing systemic toxicity associated with systemic IL-2 administration[1][4]. Preclinical studies have shown robust tumor colonization and synergistic effects with chemotherapy agents such as doxorubicin[4][5]. Clinical trials have demonstrated safety in humans and increases in NK cell populations; ongoing Phase II trials are evaluating its efficacy in combination with standard chemotherapies for metastatic pancreatic cancer[3][4][5].
- Brand names
- Saltikva
- Other names
- recombinant attenuated Salmonella typhimurium expressing IL-2
02
Targets
IL-2R (Interleukin-2/interleukin-15 receptor complex)
Beyond the preview
Go deeper on Salmonella-IL2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Salmonella-IL2.